Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far.
Ontology highlight
ABSTRACT: Angiogenesis, the formation of new blood vessels, is an essential component of glioblastoma (GB) progression. The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits relative to standard treatment. There are several possible reasons for this limited efficacy, including VEGF-independent angiogenesis, induction of tumor invasion, and inefficient antiangiogenic factor delivery to the tumor. Efforts have been made to overcome these limitations by identifying new angiogenesis inhibitors that target angiogenesis through different mechanisms of action without inducing tumor invasion, and through the deve
SUBMITTER: Clavreul A
PROVIDER: S-EPMC6461002 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
ACCESS DATA